bluebird bio Overview
Pro stress-test →Bluebird bio is a biotechnology company that researches, develops, and commercializes transformative gene therapies for severe genetic diseases, with FDA-approved therapies for transfusion-dependent β-thalassemia, sickle cell disease, and cerebral adrenoleukodystrophy. The company faces significant financial headwinds, with a market capitalization of $48.67M as of May 28, 2026, and is navigating acquisition processes by private equity firms.
Strategic Profile
Pro stress-test →The company operates a commercial-stage gene therapy business for severe genetic diseases with completed acquisition by funds managed by Carlyle and SK Capital. Bluebird's competitive advantage lies in its FDA-approved gene therapy portfolio, though the company faces challenges related to manufacturing scale-up, payer partnerships, and patient access infrastructure needed to commercialize these transformative therapies at scale.
Competitive Landscape
Pro stress-test →Bluebird bio competes in the gene therapy space against major pharmaceutical and biotech players including Vertex Pharmaceuticals (CRISPR-Cas9 programs), Sangamo Therapeutics (zinc finger nuclease therapies), and emerging players like CRISPR Therapeutics and Editas Medicine. The company's key competitive advantage is its portfolio of already-approved therapies, but it faces challenges in manufacturing scale-up and commercial distribution against better-capitalized competitors.
Industry Context
bluebird bio operates in Gene Therapy & Cell Therapy.
Key facts
Founded: 2010 · Headquarters: Cambridge, US · Revenue: $103.95M · Market cap: $48.67M